Compugen applies its Unigen computational platform, which integrates AI and machine learning, to discover novel immuno-oncology targets and develop first-in-class antibody therapeutics. Its clinical-stage programs feature COM701, an anti-PVRIG antibody, and COM902, an anti-TIGIT antibody, evaluated in solid tumor indications often in combination with other agents. Development partnerships exist with pharmaceutical companies including Bristol-Myers Squibb, AstraZeneca, and Gilead.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q1 2025 | 2.3 | — | -7.2 | — |
| Q2 2025 | 1.3 | — | -7.3 | — |
| Q3 2025 | 1.9 | — | -7 | — |
| Q4 2025 | 67.3 | — | 56.8 | — |
| Q1 2026 | 2.2 | -4.7% | -7.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Patriot Acquisition Corp. (PTAC), QumulusAI, Inc. (QMLS), Velo3D, Inc. (VELO), DSC Holdings Ltd. (DSC), Eledon Pharmaceuticals, Inc. (ELDN), CF Bankshares Inc. (CFBK)